Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain.
The endocannabinoid system consists of cannabinoid CB(1) and CB(2) receptors, endogenous ligands and their synthesising/metabolising enzymes. Cannabinoid receptors are present at key sites involved in the relay and modulation of nociceptive information. The analgesic effects of cannabinoids have been well documented. The usefulness of nonselective cannabinoid agonists can, however, be limited by psychoactive side effects associated with activation of CB(1) receptors. Following the recent evidence for CB(2) receptors existing in the nervous system and reports of their up-regulation in chronic pain states and neurodegenerative diseases, much research is now aimed at shedding light on the role of the CB(2) receptor in human disease. Recent studies have demonstrated anti-nociceptive effects of selective CB(2) receptor agonists in animal models of pain in the absence of CNS side effects. This review focuses on the analgesic potential of CB(2) receptor agonists for inflammatory, post-operative and neuropathic pain states and discusses their possible sites and mechanisms of action.
Jhaveri
Maulik D
MD
Institute of Neuroscience, School of Biomedical Sciences, University of Nottingham, Nottingham, UK. maulik.jhaveri@nottingham.ac.uk
Sagar
Devi R
DR
Elmes
Steven J R
SJ
Kendall
David A
DA
Chapman
Victoria
V
D000208:Acute Disease; D000818:Animals; D002908:Chronic Disease; D004195:Disease Models, Animal; D006801:Humans; D009619:Nociceptors / Q000378:metabolism*; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism* / Q000517:prevention & control; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000378:metabolism*
D043885:Receptor, Cannabinoid, CB2